Navigating the new normal: Debating the place of high-efficacy vs escalation treatment approaches in multiple sclerosis

18 November 2020

18:00–19:00 GMT

Job bag: MUL20-E063h | Date of preparation: November 2020

This meeting is organised and funded by Novartis Pharmaceuticals UK Limited

Adverse events should be reported. Reporting forms and information can be found at

Adverse events should also be reported to Novartis via or online through the Patient Safety Information (PSI) tool at

If you have a question about a Novartis product, please contact Medical Information on 01276 698370 or by email at

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.